Novo Nordisk A/S $NVO Shares Purchased by Generate Investment Management Ltd

Key Points

• Generate Investment Management Ltd increased its holdings in Novo Nordisk A/S by 301.7% during Q2, acquiring over 120,000 shares, bringing its total to approximately $11 million.
• Analysts have mixed ratings on Novo Nordisk, with one Strong Buy rating, six Buy ratings, and a consensus price target of $81.00.
• Novo Nordisk A/S's latest earnings showed a net margin of 35.60% and an EPS of $0.97, exceeding expectations but reported revenues lower than anticipated.

Generate Investment Management Ltd grew its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 301.7% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 160,539 shares of the company's stock after purchasing an additional 120,577 shares during the period. Generate Investment Management Ltd's holdings in Novo Nordisk A/S were worth $11,080,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Copeland Capital Management LLC increased its position in shares of Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after acquiring an additional 255 shares during the period. North Capital Inc. purchased a new stake in Novo Nordisk A/S during the 1st quarter worth about $27,000. Stone House Investment Management LLC acquired a new stake in Novo Nordisk A/S in the 1st quarter valued at about $30,000. Disciplina Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock valued at $33,000 after buying an additional 297 shares during the period. Finally, Spirit of America Management Corp NY purchased a new stake in shares of Novo Nordisk A/S during the first quarter worth approximately $35,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on NVO shares. BNP Paribas upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research note on Wednesday, August 13th. Berenberg Bank raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Wednesday, September 17th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, September 9th. UBS Group lowered shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 5th. Finally, TD Cowen reduced their price objective on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating for the company in a research report on Tuesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and a consensus price target of $81.00.

Novo Nordisk A/S Trading Down 0.8%

Shares of Novo Nordisk A/S stock opened at $55.61 on Monday. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $121.34. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The business has a 50 day moving average price of $56.03 and a 200 day moving average price of $64.38. The company has a market capitalization of $248.30 billion, a P/E ratio of 15.28, a P/E/G ratio of 2.11 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.69 billion for the quarter, compared to analysts' expectations of $77.51 billion. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio is 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.